

Deanna L Kelly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3437513/publications.pdf>

Version: 2024-02-01

162
papers

6,233
citations

71061

41
h-index

82499

72
g-index

163
all docs

163
docs citations

163
times ranked

6265
citing authors

#	ARTICLE	IF	CITATIONS
1	Can the current schizophrenia construct endure?. Schizophrenia Research, 2022, 242, 64-66.	1.1	4
2	A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training. Behavioral Sciences (Basel, Switzerland), 2022, 12, 60.	1.0	2
3	25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia. Journal of Psychiatric Research, 2022, 151, 25-29.	1.5	1
4	Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness. Schizophrenia Research, 2022, 243, 163-169.	1.1	3
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
6	Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 995-1011.	1.0	5
7	Feasibility and patient-reported satisfaction using a novel point-of-care novel fingerstick method for monitoring absolute neutrophil count (ANC) monitoring for clozapine at the point of care. , 2021, 33, 116-123.		1
8	Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2021, 41, 236-243.	0.7	13
9	Can language use in social media help in the treatment of severe mental illness?. , 2021, 1, 1-4.		1
10	Mediated Electrochemical Probing: A Systems-Level Tool for Redox Biology. ACS Chemical Biology, 2021, 16, 1099-1110.	1.6	13
11	The Role of Board-Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes. Psychiatric Services, 2021, 72, 794-801.	1.1	20
12	Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry Research, 2021, 302, 114030.	1.7	3
13	Levels of prolactin and testosterone and associated sexual dysfunction and breast abnormalities in men with schizophrenia treated with antipsychotic medications. Journal of Psychiatric Research, 2021, 143, 50-53.	1.5	12
14	Association of acute psychosocial stress with oxidative stress: Evidence from serum analysis. Redox Biology, 2021, 47, 102138.	3.9	14
15	A reduced-graphene oxide-modified microelectrode for a repeatable detection of antipsychotic clozapine using microliters-volumes of whole blood. Talanta, 2020, 209, 120560.	2.9	16
16	Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatric Quarterly, 2020, 91, 137-145.	1.1	8
17	Comparison of Novel Immunoassay With Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for Therapeutic Drug Monitoring of Clozapine. Therapeutic Drug Monitoring, 2020, 42, 771-777.	1.0	11
18	Blinded Clinical Ratings of Social Media Data are Correlated with In-Person Clinical Ratings in Participants Diagnosed with Either Depression, Schizophrenia, or Healthy Controls. Psychiatry Research, 2020, 294, 113496.	1.7	6

#	ARTICLE	IF	CITATIONS
19	A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation. <i>Schizophrenia Bulletin Open</i> , 2020, 1, sgaa001.	0.9	4
20	L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	0
21	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	1.4	102
22	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, E1-E2.	1.4	1
23	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	86
24	Treatments for the Prevention and Management of Suicide. <i>Annals of Internal Medicine</i> , 2020, 172, 167.	2.0	1
25	The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 317-319.	0.7	3
26	Validation of oxidative stress assay for schizophrenia. <i>Schizophrenia Research</i> , 2019, 212, 126-133.	1.1	15
27	Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 269-276.	1.4	22
28	<p>Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2365-2370.	1.0	19
29	Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia. <i>Schizophrenia Research</i> , 2019, 211, 111-112.	1.1	26
30	Clozapine-associated renal failure: A case report and literature review. <i>Mental Health Clinician</i> , 2019, 9, 124-127.	0.5	8
31	F88. CHILDHOOD SEXUAL ABUSE AND ADULT SEXUAL BEHAVIOR IN WOMEN WITH ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S287-S287.	2.3	0
32	T85. THE EFFECT OF ADJUNCT ARIPIPRAZOLE ON MEASURES OF TOBACCO USE AND CRAVING IN WOMEN WITH PSYCHOTIC DISORDERS. <i>Schizophrenia Bulletin</i> , 2019, 45, S236-S236.	2.3	0
33	S79. HEALTH STATUS OF PREMENOPAUSAL WOMEN WITH SCHIZOPHRENIA HAVING HYPERPROLACTINEMIA. <i>Schizophrenia Bulletin</i> , 2019, 45, S337-S337.	2.3	0
34	S115. NOVEL TECHNIQUES FOR THERAPEUTIC DRUG MONITORING FOR CLOZAPINE LEVELS. <i>Schizophrenia Bulletin</i> , 2019, 45, S350-S351.	2.3	0
35	Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG). <i>Schizophrenia Research</i> , 2019, 208, 414-419.	1.1	13
36	Redox Is a Global Biodevice Information Processing Modality. <i>Proceedings of the IEEE</i> , 2019, 107, 1402-1424.	16.4	37

#	ARTICLE	IF	CITATIONS
37	The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia. <i>Psychological Medicine</i> , 2019, 49, 1731-1739.	2.7	16
38	Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. <i>Psychiatric Quarterly</i> , 2019, 90, 351-359.	1.1	10
39	The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report. <i>Journal of Psychiatry and Brain Science</i> , 2019, 4, .	0.3	4
40	Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management. <i>Mental Health Clinician</i> , 2019, 9, 64-69.	0.5	8
41	Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. <i>Physiology and Behavior</i> , 2018, 189, 86-91.	1.0	7
42	Signal processing approach to probe chemical space for discriminating redox signatures. <i>Biosensors and Bioelectronics</i> , 2018, 112, 127-135.	5.3	17
43	The Role of Microsystems Integration Towards Point-of-Care Clozapine Treatment Monitoring in Schizophrenia. , 2018, 2, 1-4.		4
44	Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels. <i>Psychiatric Quarterly</i> , 2018, 89, 73-80.	1.1	14
45	Anti gliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2018, 69, 57-59.	2.0	18
46	Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 409-411.	1.1	23
47	Addressing Barriers to Clozapine Underutilization: A National Effort. <i>Psychiatric Services</i> , 2018, 69, 224-227.	1.1	75
48	Gliadin-related antibodies in schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 585-586.	1.1	13
49	Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia. <i>Journal of Neuropsychiatry (Foster City, Calif)</i> , 2018, 02, .	0.1	14
50	Increased circulating regulatory T cells in medicated people with schizophrenia. <i>Psychiatry Research</i> , 2018, 269, 517-523.	1.7	31
51	Relationship of Interferon- $\hat{3}$ to Cognitive Function in Midlife Women with Schizophrenia. <i>Psychiatric Quarterly</i> , 2018, 89, 937-946.	1.1	12
52	Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 317-326.	0.7	25
53	Clozapine in Reducing Aggression and Violence in Forensic Populations. <i>Psychiatric Quarterly</i> , 2018, 89, 157-168.	1.1	30
54	Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018, 12, 23-30.	1.4	30

#	ARTICLE	IF	CITATIONS
55	Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia. <i>Psychiatric Annals</i> , 2018, 48, 224-231.	0.1	1
56	Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia. <i>Schizophrenia Research</i> , 2017, 185, 200-201.	1.1	10
57	The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study. <i>Schizophrenia Research</i> , 2017, 188, 141-143.	1.1	10
58	Predictors of the Perception of Smoking Health Risks in Smokers With or Without Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2017, 13, 29-35.	0.7	7
59	Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2017, 13, 36-42.	0.7	7
60	The interplay of electrode- and bio-materials in a redox-cycling-based clozapine sensor. <i>Electrochemistry Communications</i> , 2017, 79, 33-36.	2.3	9
61	Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine. <i>Biosensors and Bioelectronics</i> , 2017, 95, 55-59.	5.3	33
62	Molecular processes in an electrochemical clozapine sensor. <i>Biointerphases</i> , 2017, 12, 02B401.	0.6	7
63	Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. <i>European Neuropsychopharmacology</i> , 2017, 27, 8-18.	0.3	69
64	Redox Probing for Chemical Information of Oxidative Stress. <i>Analytical Chemistry</i> , 2017, 89, 1583-1592.	3.2	46
65	The Analgesic Acetaminophen and the Antipsychotic Clozapine Can Each Redox-Cycle with Melanin. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2766-2777.	1.7	11
66	Connecting Biology to Electronics: Molecular Communication via Redox Modality. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700789.	3.9	40
67	122. High Antigliadin Antibodies (IgG) are Linked to Peripheral and Central Measures of Inflammation in a Subset of People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S68-S68.	2.3	1
68	Pharmacokinetics and Safety Assessment of α -Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 151-160.	1.0	23
69	Blood Pressure and Heart Rate Changes During Clozapine Treatment. <i>Psychiatric Quarterly</i> , 2017, 88, 545-552.	1.1	8
70	Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 104.	1.3	24
71	The Binding Effect of Proteins on Medications and Its Impact on Electrochemical Sensing: Antipsychotic Clozapine as a Case Study. <i>Pharmaceuticals</i> , 2017, 10, 69.	1.7	6
72	Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies. <i>Psychosomatic Medicine</i> , 2016, 78, 931-939.	1.3	24

#	ARTICLE	IF	CITATIONS
73	Bloodâ€‘brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. <i>Molecular Autism</i> , 2016, 7, 49.	2.6	324
74	Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 165-168.	1.1	21
75	Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels. <i>Advanced Healthcare Materials</i> , 2016, 5, 2595-2616.	3.9	16
76	Schizophrenia clinical symptom differences in women vs. men with and without a history of childhood physical abuse. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2016, 10, 5.	1.2	34
77	Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1454-e1459.	1.1	15
78	Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal. <i>primary care companion for CNS disorders, The</i> , 2016, 18, .	0.2	2
79	Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. <i>Human Psychopharmacology</i> , 2015, 30, 350-355.	0.7	4
80	Programmable â€‘Semismartâ€‘Sensor: Relevance to Monitoring Antipsychotics. <i>Advanced Functional Materials</i> , 2015, 25, 2156-2165.	7.8	23
81	Multidimensional Mapping Method Using an Arrayed Sensing System for Cross-Reactivity Screening. <i>PLoS ONE</i> , 2015, 10, e0116310.	1.1	10
82	Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 374-381.	0.7	81
83	Undiagnosed Lyme disease in adults with schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 579-580.	1.1	5
84	Risk-taking in schizophrenia and controls with and without cannabis dependence. <i>Schizophrenia Research</i> , 2015, 161, 471-477.	1.1	23
85	An Electrochemical Micro-System for Clozapine Antipsychotic Treatment Monitoring. <i>Electrochimica Acta</i> , 2015, 163, 260-270.	2.6	17
86	Improvement in Psychotic Symptoms After a Gluten-Free Diet in a Boy With Complex Autoimmune Illness. <i>American Journal of Psychiatry</i> , 2015, 172, 219-221.	4.0	19
87	Response to Dellâ€™Osso and Elli. <i>American Journal of Psychiatry</i> , 2015, 172, 686-686.	4.0	0
88	Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 900-908.	2.3	17
89	The risk of suicide after clozapine discontinuation: Cause for concern. <i>Annals of Clinical Psychiatry</i> , 2015, 27, 253-6.	0.6	16
90	Electrochemical Study of the Catechol-Modified Chitosan System for Clozapine Treatment Monitoring. <i>Langmuir</i> , 2014, 30, 14686-14693.	1.6	31

#	ARTICLE	IF	CITATIONS
91	Redox cycling-based amplifying electrochemical sensor for in situ clozapine antipsychotic treatment monitoring. <i>Electrochimica Acta</i> , 2014, 130, 497-503.	2.6	36
92	Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 539-542.	1.1	27
93	Complexity of oxytocin's effects in a chronic cocaine dependent population. <i>European Neuropsychopharmacology</i> , 2014, 24, 1483-1491.	0.3	44
94	Simultaneous determination of l-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: Application in clinical studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 965, 39-44.	1.2	16
95	Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. <i>Schizophrenia Research</i> , 2014, 152, 315-316.	1.1	5
96	A review of anti-inflammatory agents for symptoms of schizophrenia. <i>Journal of Psychopharmacology</i> , 2013, 27, 337-342.	2.0	89
97	Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic) <i>TJ ETQq1 1 0.784314 r8BT /Over</i>	1.1	14
98	The effect of Vitamin C for point-of-care blood analysis applications using an electrochemical biosensor. , 2013, , .		0
99	Elevated gliadin antibody levels in individuals with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 509-515.	1.3	33
100	Increased Prevalence of Transglutaminase 6 Antibodies in Sera From Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2013, 39, 867-871.	2.3	36
101	Catechol-modified Chitosan System as a Bio-amplifier for Schizophrenia Treatment Analysis. <i>Materials Research Society Symposia Proceedings</i> , 2013, 1572, 1.	0.1	2
102	Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 118-120.	0.7	3
103	Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2012, 37, 660-668.	2.8	102
104	The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use. <i>Journal of Dual Diagnosis</i> , 2012, 8, 50-61.	0.7	24
105	Perception of Smoking Risks and Motivation to Quit Among Nontreatment-Seeking Smokers With and Without Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 543-551.	2.3	43
106	Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. <i>Journal of Psychiatric Research</i> , 2012, 46, 987-993.	1.5	26
107	Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial. <i>Schizophrenia Research</i> , 2012, 134, 207-210.	1.1	47
108	Reduced arterial compliance in patients with psychiatric diagnoses. <i>Schizophrenia Research</i> , 2012, 137, 251-253.	1.1	9

#	ARTICLE	IF	CITATIONS
109	Clinical characteristics of heavy and non-heavy smokers with schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 285-289.	1.1	19
110	Illicit drug use in heavy smokers with and without schizophrenia. <i>Schizophrenia Research</i> , 2012, 139, 194-200.	1.1	7
111	A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. <i>Schizophrenia Research</i> , 2012, 140, 262-263.	1.1	51
112	Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity. <i>Psychiatric Quarterly</i> , 2012, 83, 91-102.	1.1	160
113	Current status of clozapine in the United States. <i>Shanghai Archives of Psychiatry</i> , 2012, 24, 110-3.	0.7	7
114	Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. <i>Schizophrenia Research</i> , 2011, 129, 94-95.	1.1	61
115	Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. <i>Schizophrenia Research</i> , 2011, 133, 257-258.	1.1	40
116	Tobacco craving in smokers with and without schizophrenia. <i>Schizophrenia Research</i> , 2011, 127, 241-245.	1.1	46
117	Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 86-91.	0.7	53
118	Exercise Program Adherence Using a 5-Kilometer (5K) Event as an Achievable Goal in People With Schizophrenia. <i>Biological Research for Nursing</i> , 2011, 13, 383-390.	1.0	19
119	Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. <i>Schizophrenia Bulletin</i> , 2011, 37, 94-100.	2.3	135
120	Cigarette Smoking and Mortality Risk in People With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 832-838.	2.3	130
121	Placebo-Controlled Trial of Atomoxetine for Weight Reduction in People with Schizophrenia Treated with Clozapine or Olanzapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 5, 17-25.	1.4	26
122	Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With Clozapine. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 304-311.	1.1	80
123	The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. <i>Schizophrenia Research</i> , 2010, 123, 86-87.	1.1	0
124	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Schizophrenia Bulletin</i> , 2010, 36, 71-93.	2.3	822
125	Nonresponse to clozapine and premorbid functioning in treatment refractory schizophrenia. <i>Comprehensive Psychiatry</i> , 2010, 51, 298-302.	1.5	12
126	Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. <i>Schizophrenia Research</i> , 2009, 107, 134-138.	1.1	26

#	ARTICLE	IF	CITATIONS
127	The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. <i>Clinical Neuropharmacology</i> , 2009, 32, 69-74.	0.2	30
128	A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 518-525.	1.1	41
129	Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice. <i>Psychiatric Quarterly</i> , 2008, 79, 111-119.	1.1	1
130	Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 161-168.	1.1	32
131	Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. <i>Schizophrenia Bulletin</i> , 2008, 34, 292-301.	2.3	26
132	Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine. <i>Annals of Clinical Psychiatry</i> , 2008, 20, 71-78.	0.6	20
133	Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia. <i>Schizophrenia Bulletin</i> , 2007, 33, 1221-1224.	2.3	86
134	Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2007, 164, 1404-1410.	4.0	203
135	Reaching for Wellness in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 453-479.	0.7	16
136	Why Not Clozapine?. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 92-95.	1.4	15
137	Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. <i>Psychiatric Quarterly</i> , 2006, 77, 81-95.	1.1	68
138	A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. <i>Psychoneuroendocrinology</i> , 2006, 31, 340-346.	1.3	85
139	Plasma concentrations of high-dose olanzapine in a double-blind crossover study. <i>Human Psychopharmacology</i> , 2006, 21, 393-398.	0.7	44
140	Treatment Considerations in Women with Schizophrenia. <i>Journal of Women's Health</i> , 2006, 15, 1132-1140.	1.5	13
141	Prevalence of Bone Mineral Density Loss in Korean Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1391-1396.	1.1	41
142	Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1404-1411.	1.1	46
143	The Prevalence of Hyperprolactinemia After Long-term Haloperidol Use in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 613-615.	0.7	20
144	Comparison of Clozapine Use in Maryland and in Victoria, Australia. <i>Psychiatric Services</i> , 2005, 56, 320-323.	1.1	44

#	ARTICLE	IF	CITATIONS
145	Cardiovascular disease in relation to weight in deceased persons with schizophrenia. <i>Comprehensive Psychiatry</i> , 2005, 46, 460-467.	1.5	11
146	First-Episode Schizophrenia. <i>Drugs</i> , 2005, 65, 1113-1138.	4.9	42
147	Thyroid Function in Treatment-Resistant Schizophrenia Patients Treated With Quetiapine, Risperidone, or Fluphenazine. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 80-84.	1.1	61
148	Sexuality and Schizophrenia: A Review. <i>Schizophrenia Bulletin</i> , 2004, 30, 767-779.	2.3	143
149	Atypical Antipsychotic Use in a State Hospital Inpatient Adolescent Population. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 75-85.	0.7	20
150	Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. <i>Journal of Psychiatric Research</i> , 2004, 38, 531-536.	1.5	57
151	Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. <i>Annals of Clinical Psychiatry</i> , 2003, 15, 181-186.	0.6	26
152	Evaluating sexual function in patients with treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2003, 63, 195-196.	1.1	14
153	The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 668-671.	0.7	73
154	Clozapine Treatment in Patients with Prior Substance Abuse. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 111-114.	0.9	24
155	Circumstances of suicide among individuals with schizophrenia. <i>Schizophrenia Research</i> , 2002, 58, 253-261.	1.1	53
156	Management of treatment resistance in schizophrenia. <i>Biological Psychiatry</i> , 2001, 50, 898-911.	0.7	305
157	Comparison of Discharge Rates and Drug Costs for Patients With Schizophrenia Treated With Risperidone or Olanzapine. <i>Psychiatric Services</i> , 2001, 52, 676-678.	1.1	17
158	Treatment of the special patient with schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 123-135.	1.8	1
159	Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. <i>Biological Psychiatry</i> , 1999, 46, 73-77.	0.7	116
160	Differential olanzapine plasma concentrations by sex in a fixed-dose study. <i>Schizophrenia Research</i> , 1999, 40, 101-104.	1.1	68
161	Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. <i>Schizophrenia Research</i> , 1998, 33, 95-101.	1.1	75
162	Weight Gain in Adolescents Treated with Risperidone and Conventional Antipsychotics Over Six Months. <i>Journal of Child and Adolescent Psychopharmacology</i> , 1998, 8, 151-159.	0.7	101